Cancer Deaths on Decline, But New Cases to Hit Record High Cancer Deaths on Decline, But New Cases to Hit Record High
CRC is now the leading cause of cancer deaths in men under age 50 and the second in women under 50, according to the latest ACS annual report on cancer trends.Medscape Medical News (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - January 22, 2024 Category: Gastroenterology Tags: Hematology-Oncology Source Type: news
The Case for Biomarker Testing in Gastroesophageal Cancer The Case for Biomarker Testing in Gastroesophageal Cancer
To take advantage of the latest targeted therapies in gastroesophageal cancer, physicians needed to identify patients who will benefit, but biomarker testing in this population continued to lag.Medscape Medical News (Source: Medscape Pathology Headlines)
Source: Medscape Pathology Headlines - January 22, 2024 Category: Pathology Tags: Hematology-Oncology Source Type: news
New Standard for Unresectable Hepatocellular Carcinoma?
(MedPage Today) -- SAN FRANCISCO -- After more than 20 years of trying, systemic therapy for unresectable liver cancer has improved outcomes with transarterial chemoembolization (TACE), a randomized trial showed.
Patients who received durvalumab... (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - January 21, 2024 Category: Gastroenterology Source Type: news
HAIP Chemo Offers OS Advantage in Advanced Intrahepatic Cholangiocarcinoma
(MedPage Today) -- SAN FRANCISCO -- Hepatic arterial infusion pump (HAIP) chemotherapy with floxuridine significantly improved overall survival (OS) in patients with advanced intrahepatic cholangiocarcinoma (iCCA), according to results from a... (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - January 21, 2024 Category: Gastroenterology Source Type: news
Radioligand Gets Big Win in High-Grade GEP Neuroendocrine Tumors
(MedPage Today) -- SAN FRANCISCO -- Adding a radioligand to standard therapy almost tripled median progression-free survival (PFS) in untreated high-grade gastroenteropancreatic neuroendocrine tumors (GEP-NETs), a randomized trial showed.
Median... (Source: MedPage Today Endocrinology)
Source: MedPage Today Endocrinology - January 21, 2024 Category: Endocrinology Source Type: news
